drugset

drugset / Trial / NCT05580172

Phase 1 Study of Oral RH324 in Advanced Non-Small Cell Lung Cancer

NCT05580172 ↗

Phase 1 Unknown 6 enrolled ReHeva Biosciences,Inc.

Non-randomizedSequentialOpen-labelOther

Summary

Phase 1 open label dose ranging study of RH324 in advanced non-small cell lung cancer

Timeline

Start: 2022-06-01
Primary completion: 2024-06-01
Completion: 2025-01-01

Outcome

Met primary endpoint

paper All study safety and tolerability primary endpoints were met. PMID 41685666 ↗

Publications

Heo JU, Rao S, Newton HB, Dowlati A, Muzic RF Jr, Kardan A. Phase 1 Trial of Withania somnifera Leaf Extract (RH324) in Advanced Non-Small Cell Lung Cancer Including [18F]FDG PET/CT as a Short-Term Metabolic Biomarker to Assess Efficacy: A Novel Model for Assessment of Complimentary Therapies in Early Phase Human Clinical Trials. Integr Cancer Ther. 2026 Jan-Dec;25:15347354251410182. doi: 10.1177/15347354251410182. Epub 2026 Feb 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	RH324	Unknown	—	Oral

Indications

No indication recorded.